Outcomes of Salvage Therapy for Oropharyngeal Cancer Recurrence Following Upfront Radiation Therapy and Prognostic Factors
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aimed to investigate the oncologic outcomes and prognostic factors of salvage treatments in patients with recurrent oropharyngeal squamous cell carcinoma (OPSCC) after radiotherapy (RT)-based treatment. Materials and Methods A cancer registry was used to retrieve the records of 337 patients treated with definitive RT or concurrent chemoradiotherapy (CRT) from 2008 to 2018 at a single institution. The poor-responder group (PRG) was defined as patients with residual or recurrent disease after primary treatment, and the oncologic outcomes for each salvage treatment method were analyzed. In addition, prognostic indicators of recurrence-free survival (RFS) and overall survival (OS) were identified in patients who underwent salvage treatment. Results After initial (C)RT, the PRG comprised 71 of the 337 patients (21.1%): 18 patients had residual disease, and 53 had recurrence after primary treatment (mean time to recurrence 19.5 months). Of these, 63 patients received salvage treatment (surgery 57.2%, re-(C)RT 23.8%, and chemotherapy 19.0%), and the salvage success rate was 47.6% at the last follow-up. The overall 2-year OS for salvage treatments was 56.4% (60.8% for the salvage surgery group and 46.2% for the salvage re-(C)RT). Salvage surgery patients with negative resection margins had better oncologic outcomes than those with close/positive resection margins. Using multivariate analyses, locoregional recurrence and residual disease after primary surgery were associated with poor outcome after salvage treatment. In Kaplan-Meier analyses, p16 status was significantly associated with OS in the initial treatment setting but not in the salvage setting. Conclusion In recurrent OPSCC after RT-based treatment, successful salvage was achieved in 56.4% patients who had undergone salvage surgery and radiation treatment. Salvage treatment methods should be selected carefully, given recurrence site as a prognostic factor for RFS.
Abstract
Purpose This study aimed to investigate the oncologic outcomes and prognostic factors of salvage treatments in patients with recurrent oropharyngeal squamous cell carcinoma (OPSCC) after radiotherapy (RT)-based treatment. Materials and Methods A cancer registry was used to retrieve the records of 337 patients treated with definitive RT or concurrent chemoradiotherapy (CRT) from 2008 to 2018 at a single institution. The poor-responder group (PRG) was defined as patients with residual or recurrent disease after primary treatment, and the oncologic outcomes for each salvage treatment method were analyzed. In addition, prognostic indicators of recurrence-free survival (RFS) and overall survival (OS) were identified in patients who underwent salvage treatment. Results After initial (C)RT, the PRG comprised 71 of the 337 patients (21.1%): 18 patients had residual disease, and 53 had recurrence after primary treatment (mean time to recurrence 19.5 months). Of these, 63 patients received salvage treatment (surgery 57.2%, re-(C)RT 23.8%, and chemotherapy 19.0%), and the salvage success rate was 47.6% at the last follow-up. The overall 2-year OS for salvage treatments was 56.4% (60.8% for the salvage surgery group and 46.2% for the salvage re-(C)RT). Salvage surgery patients with negative resection margins had better oncologic outcomes than those with close/positive resection margins. Using multivariate analyses, locoregional recurrence and residual disease after primary surgery were associated with poor outcome after salvage treatment. In Kaplan-Meier analyses, p16 status was significantly associated with OS in the initial treatment setting but not in the salvage setting. Conclusion In recurrent OPSCC after RT-based treatment, successful salvage was achieved in 56.4% patients who had undergone salvage surgery and radiation treatment. Salvage treatment methods should be selected carefully, given recurrence site as a prognostic factor for RFS.
참고문헌 (25)
- Chaturvedi AK, "Human papillomavirus and rising oropharyngeal cancer incidence in the United States", J Clin Oncol, 29, pp.4294~4301 (2011)
- Ang KK, "Human papillomavirus and survival of patients with oropharyngeal cancer", N Engl J Med, 363, pp.24~35 (2010)
- Chen AY, "Changes in treatment of advanced oropharyngeal cancer, 1985-2001", Lar-yngoscope, 117, pp.16~21 (2007)
- Cohan DM, "Oropharyngeal cancer : current understanding and management", Curr Opin Otolaryngol Head Neck Surg, 17, pp.88~94 (2009)
- Fakhry C, "Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial", J Natl Cancer Inst, 100, pp.261~269 (2008)
- Roosli C, "Salvage treatment for recurrent oropharyngeal squamous cell carcinoma", Head Neck, 32, pp.989~996 (2010)
- Kano S, "Salvage surgery for recurrent oropharyngeal cancer after chemoradiotherapy", Int J Clin Oncol, 18, pp.817~823 (2013)
- Ang KK, "Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma : RTOG 0522", J Clin Oncol, 32, pp.2940~2950 (2014)
- Culie D, "Oropharyngeal cancer : first relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study", Eur J Cancer, 143, pp.168~177 (2021)
- Christopherson KM, "Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation", Oral Oncol, 113, pp.105125~ (2021)
- Heft Neal ME, "Predictors and prevalence of nodal disease in salvage oropharyngectomy", Ann Surg Oncol, 27, pp.451~457 (2020)
- Hay A, "Outcomes of salvage surgery for the oropharynx and larynx : a contemporary experience in a UK Cancer Centre", Eur Arch Otorhinolaryngol, 276, pp.1153~1159 (2019)
- Sweeny L, "Outcomes after surgical salvage for recurrent oropharyngeal squamous cell carcinoma", Oral Oncol, 60, pp.118~124 (2016)
- Yoon HG, "Early clinical outcomes of intensity modulated radiation therapy", intensity modulated proton therapy combination in comparison with intensity modulated radiation therapy alone in oropharynx cancer patients, 2021, pp.13, 1549~
- Edge SB, "The American Joint Committee on Cancer : the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- -fluorodeoxyglucose positron emission tomography, "computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer", Clin Cancer Res, 15, pp.5861~5868 (2009)
- Fakhry C, "Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma", J Clin Oncol, 32, pp.3365~3373 (2014)
- Guo T, "Surgical salvage improves overall survival for pati-ents with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer", Cancer, 121, pp.1977~1984 (2015)
- Patel SN, "Salvage surgery for locally recurrent oropharyngeal cancer", Head Neck, 38(Suppl 1), pp.E658~64 (2016)
- Kao SS, "Survival outcomes following salvage surgery for oropharyngeal squamous cell carcinoma : systematic review", J Laryngol Otol, 132, pp.299~313 (2018)
- Zafereo ME, "The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx", Cancer, 115, pp.5723~5733 (2009)
- Joseph AW, "Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma", Head Neck, 38(Suppl 1), pp.E1501~9 (2016)
- Kostrzewa JP, "Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer", Laryngoscope, 120, pp.267~272 (2010)
- Boscolo-Rizzo P, "Long-term quality of life after treatment for locally advanced oropharyngeal carcinoma : surgery and postoperative radiotherapy versus concurrent chemoradiation", Oral Oncol, 45, pp.953~957 (2009)
- Nichols AC, "Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma(ORATOR) : an open-label, phase 2, randomised trial", Lancet Oncol, 20, pp.1349~1359 (2019)